Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Viviane C Veiga,João Prats,Danielle Leão Cordeiro de Farias,Regis Goulart Rosa,Letícia K. Dourado,Fernando G. Zampieri,Flávia Ribeiro Machado,Renato D. Lopes,Otavio Berwanger,Luciano Cesar Pontes Azevedo,Alvaro Avezum,Thiago Lisboa,Salomón Soriano Ordinola Rojas,Juliana C Coelho,Rodrigo T Leite,Júlio César de Carvalho,Luis Eduardo Coelho Andrade,Alex Freire Sandes,Maria Carolina Pintao,Claudio G Castro,Sueli V Santos,Thiago Miranda Lopes de Almeida,André Nathan Costa,Otavio Gebara,Flávio Geraldo Rezende Freitas,Eduardo Souza Pacheco,David J B Machado,Josiane Martin,Fábio G Conceição,Suellen R R Siqueira,Lucas P. Damiani,Luciana M Ishihara,Daniel Schneider,Denise de Souza,Alexandre Biasi Cavalcanti,Phillip Scheinberg +35 more
Reads0
Chats0
TLDR
Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.Abstract:
Objective To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial. Setting Nine hospitals in Brazil, 8 May to 17 July 2020. Participants Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin). The data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group. Interventions Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard care alone (n=64). Main outcome measure The primary outcome, clinical status measured at 15 days using a seven level ordinal scale, was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met. Results A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up. All patients in the tocilizumab group and two in the standard care group received tocilizumab. 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32). Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2). Adverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab. Conclusions In patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality. Trial registration ClinicalTrials.gov NCT04403685.read more
Citations
More filters
Journal ArticleDOI
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
TL;DR: In this paper, the authors evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial, which used a Bayesian statistical model with predefined criteria for superiority, efficacy, equivalence or futility.
Journal ArticleDOI
Drug treatments for covid-19: living systematic review and network meta-analysis.
Reed A C Siemieniuk,Jessica J Bartoszko,Long Ge,Dena Zeraatkar,Ariel Izcovich,Elena Kum,Hector Pardo-Hernandez,Anila Qasim,Juan Pablo Diaz Martinez,Bram Rochwerg,Francois Lamontagne,Mi Ah Han,Qin Liu,Arnav Agarwal,Arnav Agarwal,Thomas Agoritsas,Derek K. Chu,Rachel Couban,Ellen Cusano,Andrea Darzi,Tahira Devji,Bo Fang,Carmen Fang,Signe Flottorp,Signe Flottorp,Farid Foroutan,Farid Foroutan,Maryam Ghadimi,Diane Heels-Ansdell,Kimia Honarmand,Liangying Hou,Xiaorong Hou,Quazi Ibrahim,Assem M. Khamis,Bonnie Lam,Mark Loeb,Maura Marcucci,Shelley McLeod,Sharhzad Motaghi,Srinivas Murthy,Reem A. Mustafa,Reem A. Mustafa,John Neary,Gabriel Rada,Irbaz Bin Riaz,Behnam Sadeghirad,Nigar Sekercioglu,Lulu Sheng,Ashwini Sreekanta,Charlotte Switzer,Britta Tendal,Lehana Thabane,George Tomlinson,Tari Turner,Per Olav Vandvik,Robin W.M. Vernooij,Andrés Viteri-García,Ying Wang,Liang Yao,Zhikang Ye,Gordon H Guyatt,Romina Brignardello-Petersen +61 more
TL;DR: Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care and the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.
Journal ArticleDOI
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby,Marion K Campbell,Enti Spata,Jonathan Emberson,Natalie Staplin,Guilherme Pessoa-Amorim,Leon Peto,Martin Wiselka,L Wiffen,Simon Tiberi,B Caplin,C Wroe,Carole Green,Paul Hine,B Prudon,T George,A Wight,J K Baillie,Buddha Basnyat,Maya H Buch,Lucy C Chappell,Jeremy N. Day,Saul N. Faust,Raph L. Hamers,Thomas Jaki,Edmund Juszczak,Katie Jeffery,Wei Shen Lim,Alan A Montgomery,Andrew D Mumford,Kathy Rowan,G Thwaites,M Mafham,Richard Haynes,Martin J Landray +34 more
TL;DR: In this paper, the authors evaluated the effects ofcilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation, and found that the drug improved survival and other clinical outcomes.
Journal ArticleDOI
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
Manu Shankar-Hari,Claire L Vale,Peter J. Godolphin,David Fisher,Higgins Jpt.,Francesca Spiga,Jelena Savović,Jelena Savović,Jayne F. Tierney,Gabriel Baron,Julie Benbenishty,Lindsay R. Berry,N Broman,Alexandre Biasi Cavalcanti,R Colman,S. De Buyser,Derde Lpg.,P Domingo,S F Omar,A Fernandez-Cruz,T Feuth,F Garcia,R Garcia-Vicuna,I Gonzalez-Alvaro,Anthony C. Gordon,Richard Haynes,Olivier Hermine,Peter Horby,Nora Horick,K Kumar,B N Lambrecht,Martin J Landray,L Leal,D J Lederer,Elizabeth Lorenzi,X Mariette,N Merchante,N A Misnan,S V Mohan,M C Nivens,J Oksi,J A Perez-Molina,R Pizov,R Porcher,S Postma,R Rajasuriar,Athimalaipet V Ramanan,P Ravaud,Pankti Reid,Abraham Rutgers,A Sancho-Lopez,Todd B. Seto,S Sivapalasingam,A S Soin,Natalie Staplin,John H. Stone,Garth W. Strohbehn,J Sunden-Cullberg,J Torre-Cisneros,L W Tsai,H. van Hoogstraten,T. van Meerten,Viviane C Veiga,P E Westerweel,Srinivas Murthy,Janet V. Diaz,John C. Marshall,Sterne Jac. +67 more
TL;DR: In this article, a prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
Journal ArticleDOI
The signal pathways and treatment of cytokine storm in COVID-19.
TL;DR: In this paper, the authors discuss the latest developments in the immunopathological characteristics of COVID-19 and focus on CS including the current research status of the different cytokines involved, and discuss the induction, function, downstream signaling and existing and potential interventions for targeting these cytokines or related signal pathways.
References
More filters
Journal ArticleDOI
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
TL;DR: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Journal ArticleDOI
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Journal ArticleDOI
The socio-economic implications of the coronavirus pandemic (COVID-19): A review.
Maria Nicola,Zaid Alsafi,Catrin Sohrabi,Ahmed Kerwan,Ahmed Al-Jabir,Christos Iosifidis,Maliha Agha,Riaz Agha +7 more
TL;DR: The socio-economic effects of COVID-19 on individual aspects of the world economy are summarised to show the need for medical supplies has significantly increased and the food sector has seen a great demand due to panic-buying and stockpiling of food products.
Journal ArticleDOI
Clinical and immunological features of severe and moderate coronavirus disease 2019.
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production, which may be of importance due to their correlation with disease severity in COVID-19.
Related Papers (5)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
John H. Stone,Matthew J. Frigault,Naomi Serling-Boyd,Ana D. Fernandes,Liam Harvey,Andrea S. Foulkes,Nora Horick,Brian C. Healy,Ruta Shah,Ana Maria Bensaci,Ann E. Woolley,Sarah Nikiforow,Nina Lin,Manish Sagar,Harry M Schrager,David S. Huckins,Matthew Axelrod,Michael D. Pincus,Jorge Fleisher,Chana A. Sacks,Michael Dougan,Crystal M. North,Yuan Di C. Halvorsen,Tara K. Thurber,Zeina Dagher,Allison K. Scherer,Rachel Wallwork,Arthur Y. Kim,Sara R. Schoenfeld,Pritha Sen,Tomas G. Neilan,Cory A. Perugino,Sebastian Unizony,Deborah S. Collier,Mark Matza,Janeth Yinh,Kathryn Bowman,Eric A. Meyerowitz,Amna Zafar,Zsofia D. Drobni,Marcy B. Bolster,Minna J. Kohler,Kristin M. D’Silva,Jonathan Dau,Megan Lockwood,Caroline Cubbison,Brittany Weber,Michael K. Mansour +47 more
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
Sterne Jac.,Srinivas Murthy,Janet V. Diaz,Arthur S. Slutsky,Judit Villar,Derek C. Angus,Djillali Annane,Azevedo Lcp.,Otavio Berwanger,Alexandre Biasi Cavalcanti,Dequin P-F.,Dequin P-F.,Bin Du,Jonathan Emberson,David Fisher,Bruno Giraudeau,Anthony C. Gordon,Anders Granholm,Cameron Green,Richard Haynes,N Heming,Higgins Jpt.,Higgins Jpt.,Peter Horby,Peter Jüni,Martin J Landray,A. Le Gouge,Marie Leclerc,Wei Shen Lim,Flávia Ribeiro Machado,Colin McArthur,Colin McArthur,Ferhat Meziani,Morten Hylander Møller,Anders Perner,M W Petersen,Jelena Savović,Jelena Savović,Bruno Martins Tomazini,Viviane C Veiga,Steven A R Webb,John C. Marshall +41 more